When will the FDA approve Intellia Therapeutics' lonvo-z?

As of Sat, 21 Nov 2026 13:04:17 UTC, Kalshi traders price Before October 2027 (93.0%), Before 2028 (93.0%), Before July 2027 (91.0%). The market has $7K in volume and closes on Sat, 01 Jan 2028.

Updated:

Current odds

OutcomeChanceYes priceNo price
Before October 202793.0%93.0¢7.0¢
Before 202893.0%93.0¢7.0¢
Before July 202791.0%91.0¢9.0¢

Market details

Resolution rules

Each outcome is a separate contract with its own rules. The rules for Before October 2027:

If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.

Sources

Related markets

More markets like this

A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use

DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.